{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:45:06Z","timestamp":1791438306398,"version":"4.3.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK084246"],"award-info":[{"award-number":["R01DK084246"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL087738"],"award-info":[{"award-number":["T32HL087738"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR0590139"],"award-info":[{"award-number":["T32AR0590139"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08AR072757"],"award-info":[{"award-number":["K08AR072757"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX002882"],"award-info":[{"award-number":["BX002882"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vanderbilt Human immunology Discovery Initiative"},{"name":"Porter Family Fund for Autoimmunity Research"},{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["KL2TR002245"],"award-info":[{"award-number":["KL2TR002245"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality in systemic sclerosis (SSc). The purpose of this study was to examine recirculating lymphocytes from SSc patients for potential biomarkers of interstitial lung disease (ILD). Peripheral blood mononuclear cells (PBMCs) were isolated from patients with SSc and healthy controls enrolled in the Vanderbilt University Myositis and Scleroderma Treatment Initiative Center cohort between 9\/2017\u20136\/2019. Clinical phenotyping was performed by chart abstraction. Immunophenotyping was performed using both mass cytometry and fluorescence cytometry combined with t-distributed stochastic neighbor embedding analysis and traditional biaxial gating. This study included 34 patients with SSc-ILD, 14 patients without SSc-ILD, and 25 healthy controls. CD21<jats:sup>lo\/neg<\/jats:sup> cells are significantly increased in SSc-ILD but not in SSc without ILD (15.4\u2009\u00b1\u200913.3% vs. 5.8\u2009\u00b1\u20090.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) or healthy controls (5.0\u2009\u00b1\u20090.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). While CD21<jats:sup>lo\/neg<\/jats:sup> B cells can be identified from a single biaxial gate, tSNE analysis reveals that the biaxial gate is comprised of multiple distinct subsets, all of which are increased in SSc-ILD. CD21<jats:sup>lo\/neg<\/jats:sup> cells in both healthy controls and SSc-ILD are predominantly tBET positive and do not have intracellular CD21. Immunohistochemistry staining demonstrated that CD21<jats:sup>lo\/neg<\/jats:sup> B cells diffusely infiltrate the lung parenchyma of an SSc-ILD patient. Additional work is needed to validate this biomarker in larger cohorts and longitudinal studies and to understand the role of these cells in SSc-ILD.<\/jats:p>","DOI":"10.1007\/s10238-021-00745-5","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:15:15Z","timestamp":1628590515000},"page":"209-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CD19\u2009+\u2009CD21lo\/neg cells are increased in systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-1578","authenticated-orcid":false,"given":"Erin M.","family":"Wilfong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine N.","family":"Vowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn E.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narender","family":"Annapureddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie B.","family":"Dudenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Barnado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Bonami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy L.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"4","key":"745_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","volume":"37","author":"H Chifflot","year":"2008","unstructured":"Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223\u201335.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"745_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"745_CR3","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/art.34482","volume":"64","author":"V Steen","year":"2012","unstructured":"Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9):2986\u201394.","journal-title":"Arthritis Rheum"},{"key":"745_CR4","doi-asserted-by":"crossref","unstructured":"Muangchan C, Canadian Scleroderma Research G, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(9):1545\u201356.","DOI":"10.3899\/jrheum.121380"},{"issue":"8","key":"745_CR5","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/art.30415","volume":"63","author":"K Hoshino","year":"2011","unstructured":"Hoshino K, Satoh T, Kawaguchi Y, Kuwana M. Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum. 2011;63(8):2465\u201372.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"745_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MD.0b013e31829be125","volume":"92","author":"AC Gelber","year":"2013","unstructured":"Gelber AC, Manno RL, Shah AA, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore). 2013;92(4):191\u2013205.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"745_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"745_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis. 2007;66(7):940\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"745_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/ard.2007.075721","volume":"67","author":"M Baron","year":"2008","unstructured":"Baron M, Sutton E, Hudson M, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis. 2008;67(5):644\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"745_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/art.20787","volume":"52","author":"D Khanna","year":"2005","unstructured":"Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005;52(2):592\u2013600.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"745_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3899\/jrheum.080633","volume":"36","author":"FN Hant","year":"2009","unstructured":"Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36(4):773\u201380.","journal-title":"J Rheumatol"},{"issue":"1","key":"745_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00003246-200301000-00003","volume":"31","author":"IW Cheng","year":"2003","unstructured":"Cheng IW, Ware LB, Greene KE, et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med. 2003;31(1):20\u20137.","journal-title":"Crit Care Med"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2466-10-6","volume":"10","author":"RM Determann","year":"2010","unstructured":"Determann RM, Royakkers AA, Haitsma JJ, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med. 2010;10:6.","journal-title":"BMC Pulm Med"},{"key":"745_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2466-7-13","volume":"7","author":"DD Sin","year":"2007","unstructured":"Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med. 2007;7:13.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"745_CR15","doi-asserted-by":"publisher","first-page":"L3","DOI":"10.1152\/ajplung.90637.2008","volume":"299","author":"HR Collard","year":"2010","unstructured":"Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3-7.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"745_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A De Lauretis","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435\u201346.","journal-title":"J Rheumatol"},{"issue":"5","key":"745_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L van Bon","year":"2014","unstructured":"van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"745_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/labinvest.2010.73","volume":"90","author":"SK Mathai","year":"2010","unstructured":"Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90(6):812\u201323.","journal-title":"Lab Invest"},{"issue":"5","key":"745_CR19","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3486","volume":"13","author":"ME Truchetet","year":"2011","unstructured":"Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011;13(5):R166.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"745_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2010.06.004","volume":"137","author":"A Giovannetti","year":"2010","unstructured":"Giovannetti A, Rosato E, Renzi C, et al. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol. 2010;137(1):122\u201333.","journal-title":"Clin Immunol"},{"issue":"7","key":"745_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jclinpath-2017-204656","volume":"71","author":"S Bosello","year":"2018","unstructured":"Bosello S, Basile U, De Lorenzis E, et al. Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. J Clin Pathol. 2018;71(7):620.","journal-title":"J Clin Pathol"},{"issue":"9","key":"745_CR22","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/art.22847","volume":"56","author":"R Lafyatis","year":"2007","unstructured":"Lafyatis R, O\u2019Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2007;56(9):3167\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"745_CR23","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"745_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625\u201331.","journal-title":"Semin Arthritis Rheum"},{"issue":"24","key":"745_CR25","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1182\/blood-2009-09-243071","volume":"115","author":"I Isnardi","year":"2010","unstructured":"Isnardi I, Ng YS, Menard L, et al. Complement receptor 2\/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood. 2010;115(24):5026\u201336.","journal-title":"Blood"},{"issue":"2","key":"745_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clim.2007.10.004","volume":"126","author":"MW Nicholas","year":"2008","unstructured":"Nicholas MW, Dooley MA, Hogan SL, et al. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol. 2008;126(2):189\u2013201.","journal-title":"Clin Immunol"},{"issue":"5","key":"745_CR27","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaci.2015.09.014","volume":"137","author":"Q Simon","year":"2016","unstructured":"Simon Q, Pers JO, Cornec D, et al. In-depth characterization of CD24(high)CD38(high) transitional human B cells reveals different regulatory profiles. J Allergy Clin Immunol. 2016;137(5):1577-84 e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"745_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20080611","volume":"206","author":"JA Duty","year":"2009","unstructured":"Duty JA, Szodoray P, Zheng NY, et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med. 2009;206(1):139\u201351.","journal-title":"J Exp Med"},{"issue":"11","key":"745_CR29","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"745_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ymeth.2015.05.008","volume":"82","author":"KE Diggins","year":"2015","unstructured":"Diggins KE, Ferrell PB Jr, Irish JM. Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. Methods. 2015;82:55\u201363.","journal-title":"Methods"},{"issue":"4","key":"745_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49(4):725-39.e6.","journal-title":"Immunity"},{"issue":"3","key":"745_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0025-6196(11)61030-6","volume":"82","author":"JH Ryu","year":"2007","unstructured":"Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82(3):342\u201350.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"745_CR33","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.4049\/jimmunol.1501209","volume":"195","author":"K Rubtsova","year":"2015","unstructured":"Rubtsova K, Rubtsov AV, Cancro MP, Marrack P. Age-associated B cells: a T-bet\u2013dependent effector with roles in protective and pathogenic immunity. J Immunol. 2015;195(5):1933\u20137.","journal-title":"J Immunol"},{"issue":"6","key":"745_CR34","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004;50(6):1918\u201327.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"745_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.autrev.2017.10.015","volume":"17","author":"A Forestier","year":"2018","unstructured":"Forestier A, Guerrier T, Jouvray M, et al. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev. 2018;17(3):244\u201355.","journal-title":"Autoimmun Rev"},{"key":"745_CR36","doi-asserted-by":"crossref","unstructured":"van der Kroef M, van den Hoogen LL, Mertens JS, et al. Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjogrens syndrome. Eur J Immunol. 2020;50(1):119\u201329.","DOI":"10.1002\/eji.201948129"},{"issue":"5","key":"745_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier N, Chaigne B, Regent A, et al. Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor beta and activate fibroblasts. Arthritis Rheumatol. 2017;69(5):1078\u201389.","journal-title":"Arthritis Rheumatol"},{"key":"745_CR38","doi-asserted-by":"publisher","first-page":"108364","DOI":"10.1016\/j.clim.2020.108364","volume":"213","author":"R Marrapodi","year":"2020","unstructured":"Marrapodi R, Pellicano C, Radicchio G, et al. CD21low B cells in systemic sclerosis: A possible marker of vascular complications. Clin Immunol. 2020;213:108364.","journal-title":"Clin Immunol"},{"issue":"7","key":"745_CR39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Gr\u00fcnig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"745_CR40","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3899\/jrheum.101243","volume":"38","author":"M Hinchcliff","year":"2011","unstructured":"Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011;38(10):2172\u20139.","journal-title":"J Rheumatol"},{"key":"745_CR41","doi-asserted-by":"crossref","unstructured":"Visentini M, Pellicano C, Leodori G, et al. CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis. Clin Exp Immunol. 2021;205(2):128\u201334.","DOI":"10.1111\/cei.13604"},{"issue":"2","key":"745_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715\u201320.","journal-title":"J Clin Invest"},{"issue":"1","key":"745_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.yexcr.2017.10.013","volume":"361","author":"S Zhu","year":"2017","unstructured":"Zhu S, Wang X, Wang J, et al. CD21(lo\/med)CD27(+) proinflammatory B cells are enriched in breast cancer patients and promote antitumor T cell responses. Exp Cell Res. 2017;361(1):149\u201354.","journal-title":"Exp Cell Res"},{"issue":"5","key":"745_CR44","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2011-01-330530","volume":"118","author":"Y Hao","year":"2011","unstructured":"Hao Y, O\u2019Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011;118(5):1294\u2013304.","journal-title":"Blood"},{"issue":"9","key":"745_CR45","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.molimm.2006.10.014","volume":"44","author":"J Tessier","year":"2007","unstructured":"Tessier J, Cuvillier A, Glaudet F, Khamlichi AA. Internalization and molecular interactions of human CD21 receptor. Mol Immunol. 2007;44(9):2415\u201325.","journal-title":"Mol Immunol"},{"issue":"1","key":"745_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/eji.1830270119","volume":"27","author":"SA Boackle","year":"1997","unstructured":"Boackle SA, Holers VM, Karp DR. CD21 augments antigen presentation in immune individuals. Eur J Immunol. 1997;27(1):122\u20139.","journal-title":"Eur J Immunol"},{"issue":"25","key":"745_CR47","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med"},{"issue":"9","key":"745_CR48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"745_CR49","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Tashkin DP, Li N, et al. mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69(7):1451\u201360.","journal-title":"Arthritis Rheumatol"},{"issue":"21","key":"745_CR50","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00745-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T18:20:57Z","timestamp":1652725257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00745-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"IRB approval was obtained through Vanderbilt University Medical Center (IRB 141415), and written consent was obtained for all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}